However, headaches are generally not among the most common adverse effects of semaglutidegastrointestinal symptoms such as nausea, diarrhea, and constipation occur more frequently
[3] Anti-inflammatory SUMMARY: The emerging research suggests that GLP-1 medications like semaglutide may help reduce systemic inflammation, a key driver behind many chronic diseases including heart disease, metabolic disorders, and some autoimmune conditions
California recently passed a budget for 2025-2026 that eliminates Medicaid coverage for GLP-1 agonists for weight loss
Dose may reach a target range depending on response
Water restriction has been demonstrated to rapidly reduce bowel movements in healthy people (Klauser 1990), and low fluid consumption has been associated with an increased risk of chronic constipation (Markland 2013)
Many individuals are finding that this treatment not only supports weight loss but also improves overall health, leading to a significant reduction in obesity-related conditions